





Corlanor (ivabradine) Prior Authorization of Benefits Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004.

	2. Physician information	on	
	Prescribing physician: _	Prescribing physician:	
Patient ID #:		Physician address:	
Patient DOB:		Physician phone #:	
	Physician fax #:		
	Physician specialty:		
	Physician DEA:		
	Physician NPI #:		
		Physician email address:	
4. Strength	5. Directions	6. Quantity per 30 days	
		Specify:	
7. Diagnosis:			
	4. Strength	Prescribing physician: Physician address: Physician phone #: Physician specialty: Physician DEA: Physician NPI #: Physician email address: S. Directions	

8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Prior authorization is required for ivabradine. Only FDA-approved dosing will be considered. Payment will be considered under the following conditions:

- 1. Patient has a diagnosis of stable, symptomatic heart failure (NYHA Class II, III or IV); and
 - a. Patient is 18 years of age or older; and
 - b. Patient has documentation of a left ventricular ejection fraction ≤ 35%; and
 - c. Patient is in sinus rhythm with a resting heart rate of ≥70 beats per minute; and
 - d. Patient has documentation of blood pressure ≥90/50 mmHg; or
- 2. Patient has a diagnosis of stable symptomatic heart failure (NYHA/Ross class II to IV) due to dilated cardiomyopathy; and
 - a. Pediatric patient age 6 months and less than 18 years old; and
 - b. Patient has documentation of a left ventricular ejection fraction ≤ 45%; and
 - c. Patient is in sinus rhythm with a resting heart rate (HR) defined below:
 - i. 6 to 12 months HR \geq 105 bpm
 - ii. 1 to 3 years HR ≥ 95 bpm
 - iii. 3 to 5 years HR ≥ 75 bpm
 - iv. 5 to 18 years HR \geq 70 bpm; and
- 3. Heart failure symptoms persist with maximally tolerated doses of at least one beta-blocker with proven mortality benefit in a heart failure clinical trial (e.g., carvedilol 50mg daily, metoprolol succinate 200mg daily,

- or bisoprolol 10mg daily), or weight appropriate dosing for pediatric patients, or patient has a documented intolerance or FDA labeled contraindication to beta-blockers; and
- 4. Patient has documentation of a trial and continued use with a preferred angiotensin system blocker at a maximally tolerated dose.
- 5. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

would be incuredly contrained cated.			
Diagnosis:			
_	o IV)): NYHA Class (≥ 18 years of age):		
	,, , , , , , , , , , , , , , , , , , , ,		
☐ Stable, symptomatic heart failure (NYHA/Ross Cla	ass II to IV) due to dilated cardiomyopathy (6 months to < 18		
years of age):NYHA/Ross Class:			
☐ Other:			
	-		
Dravida left ventricular ciaction fraction. Data obta	inadi		
Provide left ventricular ejection fraction: Date obta	s rhythm:		
	Date obtained:		
For diagnosis of stable, symptomatic heart failure (NYHA Class II, III, or IV) in members ≥ 18 years of age:		
Does patient have blood pressure ≥90/50mmHg?			
□ No □ Yes Blood pressure:	Date obtained:		
	f beta-blocker with proven mortality benefit in a heart failure		
clinical trial:			
	Trial dates:		
Reason for failure:			
Contraindication:			
Trial and continued use with a preferred angiotens	sin system blocker at maximally tolerated dose:		
	Trial dates:		
Will an angiotensin system blocker be used concomitantly with ivabradine? \square No \square Yes			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Attach lab results and other documentation as nec	essary.		
9. Physician signature			
Described an expectation of circulations	- Data		
Prescriber or authorized signature	Date		
Prior Authorization of Renefits is not the practice of	medicine or the substitute for the independent medical judgment		
	n determine what medications are appropriate for a patient.		
	formation regarding benefits, conditions, limitations, and		
• • • • • •	e information provided is true, accurate, and complete and the		
requested services are medically indicated and necessary to the health of the patient.			
Note: Payment is subject to member eli	igibility. Authorization does not guarantee payment.		